Synthesis and analysis of contaminants in EMS-related tryptophan

Advances in Experimental Medicine and Biology

Volumn 398, Issue , 1996, Pages 667-675

  Steinhart, H ^a   Van Wickern, B ^a   Meyer, K ^a   Simat, T ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' ETHYLIDENE BIS(TRYPTOPHAN); 1,1'-ETHYLIDENE BIS(TRYPTOPHAN); 3 (PHENYLAMINO)ALANINE; 3-(PHENYLAMINO)ALANINE; ALANINE; DRUG DERIVATIVE; TRYPTOPHAN; TRYPTOPHANASE;

ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG CONTAMINATION; EOSINOPHILIA MYALGIA SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; STANDARD; SYNTHESIS;

ALANINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; EOSINOPHILIA-MYALGIA SYNDROME; HUMANS; TRYPTOPHAN; TRYPTOPHANASE;

EID: 0030341986     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4613-0381-7_108     Document Type: Article

References (13)

1. Belongia, E.A., Hedberg, C.W., Gleich, G.J., White, K.E., Mayeno, A.N., Loegering, D.A., Dunette, S.L., Pirie, P.L., MacDonald, K.L., and Osterholm, M.T., 1990, An investigation of the cause of the eosinophiliamyalgia syndrome associated with tryptophan use, N. Engl. J. Med. 323:357.
2. Feiden, 1994, Monographie Tryptophan, Deutsche Apotheker Zeitung 134:3361.
3. Goda, Y., Suzuki, J., Maitani, T., Yoshihira, K., Takeda, M., and Uchiyama, M., 1992, 3-Anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples, Chem. Pharm. Bull. 40:2236.
4. Hertzman, P.A., Falk, H., Kilbourne, E.M., Page, S., and Shulman, L.E., 1991, The eosinophilia-myalgia syndrome: The Los Alamos conference, J. Rheumatol. 18:867.
5. Hill, R.H. Jr., Caudill, S.P., Philen, R.M., Bailey, S.L., Flanders, W.D., Driskell, W.J., Kamb, M.L., Needham, L.L., and Sampson, E.J., 1993, Contaminants in L-tryptophan associated with cosinophilia myalgia syndrome, Arch. Environ. Contam. Toxicol. 25:134.
6. Müller, A., Busker, E., Günther, K., and Hoppe B., 1991, Characterization of byproducts in L-tryptophan, Bioforum 14:350.
7. Philen, R.M., Hill, R.F. Jr., Flanders, W.D., Caudill, S.P., Needham, L., Sewell, L., Sampson, E.J., Falk, H., Kilbourne, E.M., and the Eosinophilia-Myalgia Studies of Oregon, New York, and New Mexico, 1993, Tryptophan contaminants associated with eosinophilia-myalgia syndrome, Am. J. of Epidemiol. 138:154.
8. Savige, W.E., 1975, New oxidation products of tryptophan, Aust. J. Chem. 28:2275.
9. Sakimoto, K. and Torigoe, Y., 1994, Study of mechanism of peak E substance formation in process for manufacture of L-tryptophan, in: L-Tryptophan Current Prospects in Medicine and Drug Safety, W. Kochen and H. Steinhart, eds., Walter de Gruyter Berlin, New York.
10. Simat, T., Meyer, K., and Steinhart, H., 1994, Synthesis and analysis of oxidation and carbonyl condensation compounds of tryptophan, J. Chromatogr. A 661:93.
11. Smith, M.J., Mazzola, E.P., Farrell, T.J., Sphon, J.A., Page, S.W., Ashley, D., Sirimanne, S.R., Hill, R.H. Jr., and Needham, L.L., 1991. 1,1'Ethylidenebis(L-tryptophan), structure determination of contaminant "97" - implicated in the eosinophilia.myalgia syndrome (EMS), Tetrahedron Lett. 32:991.
12. Toyoda, M., Saito, Y., Uchiyama, M., Troy, A.L., Trucksess, M.W., and Page, S.W., 1994, Formation of 3-(phenylamino)alanine contaminant in EMS-associated L-tryptophan, Biosci. Biotech. Biochem. 58:1318.
13. Toyo'oka, T., Yamazaki, T., Tanimoto, T., Sato, K., Sato, M., K., Toyoda, M., Ishibashi, M., Yoshihira, K., and Uchiyama, M., 1991. Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography, Chem. Pharm. Bull. 39:820.